Edesa Biotech Files 8-K

TL;DR

Edesa Biotech filed an 8-K on 10/28/25 for an 'Other Event' - details pending.

AI Summary

Edesa Biotech, Inc. filed an 8-K on October 28, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, but it confirms the company's reporting status and principal executive offices located at 100 Spy Court, Markham, Ontario, Canada.

Why It Matters

This filing indicates a material event has occurred for Edesa Biotech, Inc., requiring public disclosure. Investors should monitor for further details to understand the event's implications.

Risk Assessment

Risk Level: medium — The filing is an 8-K for an 'Other Event' without immediate disclosed specifics, suggesting a potentially significant but currently undefined development.

Key Players & Entities

• Edesa Biotech, Inc. (company) — Registrant
• October 28, 2025 (date) — Date of earliest event reported
• 100 Spy Court, Markham, Ontario, Canada L3R 5H6 (address) — Principal Executive Offices
• Stellar Biotechnologies, Inc. (company) — Former company name

FAQ

Filing Documents

• f8k_102825.htm (8-K) — 29KB
• 0001171843-25-006690.txt ( ) — 190KB
• edsa-20251028.xsd (EX-101.SCH) — 3KB
• edsa-20251028_lab.xml (EX-101.LAB) — 33KB
• edsa-20251028_pre.xml (EX-101.PRE) — 22KB
• f8k_102825_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On October 8, 2025, Edesa Biotech, Inc. (the "Company") announced positive results from a Phase 3 study evaluating the Company's drug candidate paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome ("ARDS"), a life-threatening form of respiratory failure. The data from the Phase 3 study demonstrated that paridiprubart met primary and secondary endpoints with statistical significance. Paridiprubart led to a clinically significant reduction in mortality through 60 days, as well as a significant reduction in the proportion of patients requiring invasive mechanical ventilation ("IMV"). Paridiprubart in the most conservative intention-to-treat ("ITT") population met the primary endpoint, demonstrating a statistically significant and clinically meaningful benefit for reduced mortality at 28 days. Patients treated with paridiprubart plus standard of care treatments ("SOC") had a lower risk of death (39%) compared to those receiving placebo (52%), representing an absolute improvement in survival of 13% at 28 days with paridiprubart demonstrating a relative reduction in the risk of death of 25% compared to placebo (n=104; p<0.001). A durable survival benefit was also demonstrated at 60 days, with patients treated with paridiprubart plus SOC demonstrating a lower risk of death (46%) compared to those receiving placebo (59%), representing an absolute improvement in survival of 13% with a relative risk reduction of 22% for paridiprubart compared to placebo (n=104; p=0.003). In addition, subjects receiving paridiprubart + SOC demonstrated a 41% higher relative rate of clinical improvement, meaning patients no longer required IMV and/or organ support at Day 28. The results from a safety population of more than 275 subjects, which included patients enrolled during the interim between the Phase 2 and Phase 3 study, demonstrated that EB05 was generally well-tolerated and consistent with the observed safety profile to date. Paridipr

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Edesa Biotech, Inc. Date: October 28, 2025 By: /s/ Peter J. Weiler Name: Peter J. Weiler Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR